SARS-CoV-2 Glycosylation Profiling

The COVID-19 pandemic has brought unprecedented challenges to the world. CD BioGlyco has combined multiple technology platforms to provide customers with comprehensive and accurate viral glycomics information to speed up the development of vaccines and other therapeutic agents. We have confidence to be your essential research assistant in the field of glycobiology.

Background 

Coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has dramatically impacted human health and the global economy. From the discovery of the virus in early January 2020 to November 2020, the virus has infected more than 60 million people worldwide and caused more than 1.4 million deaths. Understanding virus attachment patterns, entry, and replication has become a critical step in interventions has become a key step in interventions.

The US FDA has approved two vaccines from Pfizer and Moderna to be distributed in the U.S. market. The scientific community is still making great efforts to understand the virus in many aspects and compile useful data. The virus uses the spike protein (S protein) to bind angiotensin-converting enzyme 2 (ACE-2) to cause infection. S protein is a highly glycosylated protein, containing 22 N-linked and 3 O-linked glycosylation sites, which is a key protein that affects virus infection and vaccine preparation. Therefore, it has become the focus of attention in academia and industry.

To better understand the variation of S protein and its potential impact on the host immune system, researchers are performing glycosylation profiling, characterizing its changes during the global spread and comparing it with the glycosylation characteristics of SARS-COV.

SARS-CoV-2 Glycosylation ProfilingFig 1. MD simulation of glycosylated soluble human ACE2 and glycosylated SARS-CoV-2 S trimer immunogen interaction. ACE2 (top) is colored red with glycans in pink, whereas S is colored white with glycans in dark gray. (Zhao, P. et al. 2020)

SARS-CoV-2 Glycosylation Profiling

Solutions

CD BioGlyco integrates our most advanced technology platforms and do our best to promote coronavirus research. We provide the following services to help scientists around the world to better study SARS-CoV-2.

  • We provide gene sequences of related proteins of SARS-CoV-2, including spike protein, nucleocapsid protein, papain-like protease, 3CL protease, as well as the related proteins such as various receptors in host cells.
  • We have a variety of glycoengineered expression systems, including HEK293, CHO, BHK, SF21, etc., to express SARS-CoV-2 related proteins according to customers' needs.
  • We provide the most comprehensive glycomics analysis platform to systematically analyze the coronavirus-related glycoproteins of interest to customers, including glycosylation profiling, comparative characterization (changes in the propagation process and the comparison with the glycosylation characteristics of SARS-COV, etc.), to provide the necessary basis for vaccine development.
  • We also provide lectin-based development services to help customers identify and characterize glycoproteins in the viral envelope or changes in glycoproteins in host cells during viral infection.

Applications

  • Vaccine development
  • Detection kit development
  • Virology Research
  • Develop tools for microarray, immunoassay, and virus purification from whole blood
  • Development of biomarkers to predict disease severity

Our Advantages

  • Efficient service with fast turnaround time
  • Guaranteed data accuracy
  • The most advanced technology platforms
  • Provide experimental data analysis in multi-fields
  • Customized one-stop service

CD BioGlyco is committed to developing various technology platforms to help scientists around the world explore the coronavirus and promote the global vaccine development process. CD BioGlyco has professional teams and ultra-high-precision instruments. We are confident that we can provide customers with high-quality viral glycomics research.

Clients can reach our scientists directly via email or phone to receive prompt response. If you are interested in our services, please contact us for more detailed information.

References:

  1. Zhao, P. et al. Virus-receptor interactions of glycosylated SARS-CoV-2 spike and human ACE2 receptor. Cell Host & Microbe. 2020, 28: 1-16.
  2. Xu, W. et al. Variations in SARS-CoV-2 spike protein cell epitopes and glycosylation profiles during global transmission course of COVID-19. Frontiers in Immunology. 2020, 11.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.